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Infections with varicella zoster virus (VZV) are
common viral infections associated with signifi-
cant morbidity. Diagnosis and management are
complex, particularly in immunocompromised pa-
tients and during pregnancy. The present recom-
mendations have been established by a multidisci-
plinary panel of specialists and endorsed by nu-
merous Swiss medical societies involved in the
medical care of such patients (Appendix). The aim
was to improve the care of affected patients and to
reduce complications. 
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This document is aimed at practising physi-
cians who treat patients with varicella zoster virus
(VZV) infections. The quality of the recommen-
dations has been evaluated and codified according
to the available evidence (table 1). 
Summary
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Introduction
Varicella zoster virus – virology and pathogenesis 
VZV is a DNA virus from the family of the
alpha herpes viruses [1, 2]. After replication at the
portal of entry, the VZV spreads via the blood into
the skin and mucosa, where further replication
takes place, causing the rash typical of varicella.
The endings of the sensory nerves in the epithe-
lium are infected. From there the VZV migrates
into the sensory ganglia where it establishes a
latent infection. During the latency period only a
few VZV genes are active. VZV can be reactivated
if the immune defences are weakened. VZV has a
thymidine kinase and a DNA polymerase, which
account for its nucleoside analogues susceptibility.
The antivirals aciclovir, valaciclovir, famciclovir
and brivudine are available for the treatment of
VZV infections, taking into account their individ-
ual indications and contra-indications (tables 3 and
5). If there is resistance to these nucleoside ana-
logues, foscarnet is the alternative treatment. 
1 These recommen-
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Evidence level Study type
I Controlled and randomised study (or systematic review of such studies)
II Controlled but not randomised study
III Prospective cohort study
IV Retrospective cohort study or case-control study
V Case-series study, expert opinion
Recommendation Evidence
level
A Good evidence to support the recommendation (in general based on evidence level I)
B Fair evidence to support the recommendation (in general based on evidence 
level II or III) 
C Inadequate evidence to support the recommendation (in general based on evidence 
level IV or V) or decision of the expert group
D Fair evidence against a recommendation (in general based on evidence level II or III) 
E Good evidence against a recommendation (in general based on evidence level I) 
Table 1 
Evidence and
recommendations.
Complication Comment
In children
Secondary bacterial infections Staphylococcus aureus and Streptococcus pyogenes are the most common 
pathogens
Cellulitis, more rarely lymphadenitis or subcutaneous abscesses
Necrotising fasciitis or toxic shock syndrome due to infection with 
exotoxin A-producing S. pyogenes
Neurological complications Second most frequent cause of hospitalisation
Cerebellitis, encephalitis, cerebellar ataxia
Very rare: 
Transverse myelitis, Guillain-Barré syndrome
Other complications Very rare: 
Hepatitis, thrombocytopenia, nephritis, arthritis, myocarditis, 
pericarditis
Pancreatitis and orchitis
In adults
Varicella pneumonia Symptoms only in 30% of patients! Mortality rate 10%
Encephalitis Incidence: 1–2/10,000; Mortality rate 5–10%
Myelitis
Scar formation
During pregnancy
Pregnant women: 
Varicella pneumonia Incidence 16%; mainly in the last trimester
Mortality rate 20–40%
Foetus:
1st- 20th week of pregnancy
Foetal varicella syndrome Risk 0.4% (1st–13th week of pregnancy)
Risk 2% (14th–20th week of pregnancy)
After the 20th week of pregnancy
Congenital varicella Occurs in the first 5–15 days post partum
Risk: Mortality rate 30%
Table 2
Complications 
of varicella.
Epidemiology
VZV has a global distribution. Varicella (chick-
enpox), the manifestation of the primary infection
with VZV, is highly contagious. 96% of suscepti-
ble subjects exposed to it develop the disease.
About 90% of primary infections occur in children
under the age of 10 years. Less than 5% of people
develop the disease after the age of 15 years [3](II).
Notably, the prevalence of primary VZV infection
is lower in tropical and subtropical countries than
in Europe and North America [4, 5]. Therefore,
individuals from tropical and subtropical countries
immigrating into Europe or North America are at
increased risk of primary VZV infection in adult-
Varicella
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hood. VZV is shed in respiratory secretions and
cutaneous lesions. Transmission is airborne or by di-
rect contact of skin and mucosa with the contents
of the blisters. The portal of entry is the upper res-
piratory mucosa and the conjunctiva. 
Varicella in children
After incubation for 10–21 days, half of all chil-
dren show prodromes (fever <39° C, malaise, head
and stomach ache). These precede by 24–72 hours
the exanthema which initially manifests itself as ex-
Indication Medicine Dosage Comments
Varicella in children (up to 12 years of age)
Prophylaxis
In immunocompetent children: Not recommended
In immunocompromised children: VZV-immunoglobulins 12.5–25 I.U. per kg i.v. Single dose <48 h after exposure 
but no later than 96 h after 
exposure
IVIG 0.4 g/kg Single dose 
(instead of VZV-IG)
Treatment
In immunocompetent children: Symptomatic topical
antiseptic therapy 
Optional systemic therapy Aciclovir 100 mg/kg/day p.o. – 5–10 days
In immunocompromised children: Systemic therapy Aciclovir 320 mg/kg/day i.v. – 5–10 days
Varicella in immunocompetent adults (within the first 24 hours)
Prophylaxis Post exposure prophylaxis active vaccination
Treatment Aciclovir 5  800 mg per day p.o. – 5–10 days 
3  10 mg/kg per day i.v – 5–10 days in severe cases
Valaciclovir 31000 mg per day p.o. – 7–10 days
Famciclovir 3500 mg per day p.o. – 7–10 days
In addition to the antivirals, the treatment of varicella includes the use of analgesics and topical therapy with disinfectants, 
silver sulphadiazine cream or a cream paste.
Varicella in immunocompromised adults
Post-exposure prophylaxis VZV immunoglobulin in VZV-seronegative immunocompromised patients 
within the first 4 days after exposure
Treatment Aciclovir 3500 mg/m2 or 10 mg/kg i.v. per day for 7–14 days
Valaciclovir 31000 mg per day p.o. – 7 days
Famciclovir 3500 mg per day p.o. – 7 days
Varicella during pregnancy
Post-exposure prophylaxis in seronegative pregnant women
VZIG or IVIG VZIG 0.2 ml/kg or IVIG 0.4 g/kg iv.
within 72–96 hours of exposure 
Treatment
Topical symptomatic treatment. Topical antiviral therapy not recommended.
Antiviral treatment Acyclovir 310 mg/kg per day i.v .– 7 days if severe or 
complications
Varicella in neonates
Prophylaxis
Indications for VZIG [59]:
Administration of VZIG immediately after birth or after postnatal exposure:
– Neonates born to mothers in whom exanthema occurs within the period from 5 (to 7) days before to 2 days after birth (B)
– Hospitalised premature babies and sick neonates with nosocomial VZV exposure (direct contact or at least one hour in the same 
room with an infectious person) with non-immune mothers (C)
– Premature babies <28 weeks of pregnancy or with a birth weight of <1000 g with nosocomial exposure irrespective 
of the mother’s serostatus (C) 
Disputed indication:
– Healthy full-term babies born to non-immune mothers with postnatal varicella exposure (most likely to be justifiable in the case 
of exposure in the home from a sibling) 
No indication:
– Brief exposure in the maternity clinic 
Treatment
In the case of systemic symptoms or severe exanthema: Acyclovir i.v. 320 mg/kg/day
Table 3
Post-exposure pro-
phylaxis and antiviral
treatment of
varicella.
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anthema on the oral mucosa and reddish macules
and papules on the scalp, face and trunk. This is
rapidly followed by itching blisters and pustules.
Different stages of efflorescence are present at 
the same time. New lesions can develop for up to
7 days. Children with varicella, after exposure in
the household, can develop fever and new lesions
even after 7 days [6]. Secondary as well as tertiary
household contacts are at increased risk for more
severe varicella and may benefit from antiviral
therapy [7]. 
The severity of the disease increases with age.
Pre-existing skin damage such as atopic dermatitis
favours a rapid spread of the exanthema [8]. Pro-
nounced scarring is extremely rare. Hypopigmen-
tation can remain for weeks. The hospitalisation
rate is 9.1/10,000 cases of varicella [9]. Serious or
even fatal outcomes have been observed in the case
of topical or systemic administration of steroids,
especially if administered during the incubation
period [10, 11]. Recurrence of varicella is ex-
tremely rare [12]. The complications of varicella in
children are listed in table 2. Reye syndrome [13]
is now only rarely observed since salicylates have
been contra-indicated in varicella.
Immunocompetent children with varicella are
treated without antivirals. Oral aciclovir shortens
the course only slightly (I) [6, 14]. In immunocom-
promised children, intravenous aciclovir is indi-
cated (table 3). Oral valaciclovir, a precursor of
aciclovir with improved bioavailability, produces
blood levels similar to those with intravenous
aciclovir [15]. Due to the limited data available in
children, use of valaciclovir can be considered only
in those immunocompromised children who
exhibit mild varicella disease (C). Children should
be kept away from kindergarten or school until the
lesions have crusted (C). Immunocompromised or
seronegative adult contacts should be identified
(C). 
Varicella in adults
Varicella in adults is associated with a more se-
vere prodrome [8]. The risk of potentially fatal
complications increases with age (table 2). The mor-
tality rate of varicella in adulthood is 17/100,000
[16] and is mainly due to varicella pneumonia [17]
(II). Pneumonia develops within 1–6 days after the
start of the exanthema. In the event of dyspnoea a
chest X-ray and hospitalisation are recommended
(C). The mortality rate of varicella pneumonia is
10% [18] (II). Encephalitis (incidence of 1-2/
10,000) is a rare complication which can manifest
within 7 days of onset of the exanthema with con-
fusion, bizarre behaviour, lethargy, meningismus
and convulsions [19] and has a mortality rate of
5–10% [20] (II). In the case of varicella in adult-
hood, antiviral therapy within 24 hours of the onset
of the exanthema is recommended [2, 21] (table 3)
(C). In susceptible immunocompetent adults VZV
disease may be prevented by post exposure active
vaccination if applied within 24 hours after expo-
sure (table 3).
Varicella in immunocompromised patients
Varicella is particularly severe and accompa-
nied by complications in immunocompromised
patients [22–24]. There is a high risk of internal
organs involvement with high morbidity and mor-
tality rates [23–26] (IV). Frequent complications
are pneumonia, which occurs in one-third of chil-
dren with leukaemia who present with varicella
[25] (IV), CNS disorders (meningo-encephalitis,
cerebellar ataxia, myelitis), PNS disorders (Guil-
lain-Barré syndrome), hepatitis and bone marrow
damage with thrombocytopenia [22]. The diagno-
sis is usually established clinically. Involvement of
the internal organs can be detected by biopsies and
VZV can be detected by means of culture, im-
munohistochemistry or PCR. In the diagnosis of
VZV pneumonia, broncho-alveolar lavage can re-
place the lung biopsy. 
Prevention of VZV infections is indicated in
immunocompromised patients [22]. As varicella is
highly contagious, seronegative immunocompro-
mised patients must be protected from patients
with varicella infection. Patients with varicella may
already be infectious 2 days before the onset of the
exanthema. If immunodeficient VZV-seronega-
tive patients nevertheless come into contact with
an infectious patient, prophylactic administration
of VZV-immunoglobulins is recommended if this
can be performed within 96 hours after contact [2]
(C). An important objective of the antiviral ther-
apy of VZV infections in immunocompromised
subjects is the prevention of visceral dissemination
[27]. It is recommended to consult specialists about
the treatment. Intravenous aciclovir is the standard
treatment for severely immunodeficient patients
(eg after allogenic stem-cell transplantation or
during treatment of a rejection reaction after solid
organ transplantation) with varicella or Herpes
zoster [2, 26, 27] (IA). For patients with less pro-
nounced immunodeficiency and in the absence of
Cutaneous: Bacterial superinfection (2–3%)
Scarring formation or granulomas 
Hypopigmentation 
Cutaneous dissemination
Ocular: Keratitis, scleritis, uveitis, chorioretinitis, 
iridocyclitis
Ptosis, mydriasis
Secondary glaucoma
Acute retinal necrosis 
(very rare in immunocompetent patients)
Neurological: Postherpetic neuralgia 
(up to 50% of patients, age-related)
Motor neuropathy (mainly in HZ of the cervical 
segments affecting the N. accessorius)
Hearing loss in Zoster oticus (0.2%)
Meningitis and meningoencephalitis (0.5%)
Acute urinary retention (in case of sacral zoster) 
(rare)
Visceral: Pneumonia
Visceral dissemination
Table 4
Complications of
Herpes zoster
(frequency in %).
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Indication Drug Dosage Comments
Indications for antiviral treatment of herpes zoster
(1) Age: >50 years
(2) Pain: moderately severe to severe pain before or at start of rash
(3) Location: H. zoster in the eye area (HZ ophthalmicus); cervical HZ (motor deficits!)
(4) Immune status: immunocompromised patients (irrespective of the reason for the immunosuppression) 
Antiviral therapy 
In immunocompetent patients:
Prophylaxis not recommended
Therapy Acyclovir 5800 mg/day p.o. – 7 days
Valaciclovir 31 g per day p.o. – 7 days
Famciclovir 2–3250 mg per day p.o. – 7 days* * dose depending on age and location
Brivudine 1125 mg per day p.o. – 7 days** ** absolute contra-indication with 
fluoropyrimidines and 5-fluorouracil and capecitabine
In addition to the antivirals, the treatment of varicella includes the use of analgesics and topical therapy with disinfectants, 
silver sulphadiazine cream or a cream paste.
In children Acyclovir 500 mg/m2 or 10 mg/kg Valaciclovir and famciclovir not licensed
(<12 years): every 8 h i.v. for 7–10 days i.v. for children <12 years
In immunocompromised patients:
Prophylaxis not recommended Risk of virus resistances after long-term
administration of antivirals for VZV
Treatment Aciclovir 500 mg/m2 or 10 mg/kg
every 8 h i.v. for 7–10 days i.v. or
5800 mg per day p.o. For moderately immunocompromised patients
without involvement of internal organs
Treatment period 7–10 days
Valaciclovir 31000 mg per day p.o. same
Famciclovir 3500 mg per day p.o. same
VZV resistance
to aciclovir Foscarnet 60 mg/kg 2–3 per day i.v. for 7–14 days
or until lesions completely healed
Treatment of Herpes zoster in pregnancy
Topical symptomatic treatment. Topical or systemic antiviral therapy not recommended.
Treatment of postherpetic neuralgia
Local anaesthetics
Lidocaine containing topical formulations
Capsaicin (0.025%) cream In the first 2 weeks must be used 5 times a day, then as required
Systemic therapy
(1) Paracetamol, Acetaminophen, NSAID
(2) Antidepressants
Amitriptyline (Saroten®) Initial dose 25 mg/ day up to 100 mg / day (Check ECG from 75 mg/day)
(3) Antiepileptics
Gabapentin (Neurontin®) 900 to 3600 mg daily Start dosage 300 mg daily
Pregabalin (Lyrica®) 600 mg daily Start dosage 150 mg daily
Carbamazepine (Tegretol®) 400 to 1600 mg daily Start dosage 100 to 200 mg daily
(4) Opioids
Tramadol 200 to 600 mg daily
Oxycodon (Oxycontin®) Initial dosage 2x10 mg daily
(5) Steroids (controversial) 60 mg/d in the first week Only in the acute phase and in combination
40 mg/d in the second week with virostatics for the first 7 days
20 mg/d in the third week Note contraindications
Other long-term treatments
Pain psychotherapy, body-centred self-perception, complementary medicine (acupuncture)
Table 5
Antiviralprophylaxis
and treatment of
herpes zoster.
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signs of visceral dissemination of VZV, high-dose
oral aciclovir, valaciclovir or famciclovir are possi-
ble alternatives [2, 28] (IB) (table 3). Varicella
during pregnancy carries a risk to the mother and
the risk of vertical, trans-placental transmission
(figure 1).
Varicella in pregnancy 
The incidence of varicella is given as one in-
fection per 2000 pregnancies, and may likely be
underestimated [29, 30] (III). The infection can be
severe in pregnant women and its most common
complication is varicella pneumonia [31] (III). It
can cause severe, acute dyspnoea and is fatal in
20–40% if left untreated  [32]. Early diagnosis and
treatment of varicella pneumonia in pregnancy is
therefore of great importance, especially in severe
forms and in the third trimester [33, 34] (B).
Antiviral therapy with aciclovir can also be given
during pregnancy and is recommended in the case
of pneumonia [35, 36] (table 3) (C). Specific
immunoglobulins are not effective in manifest
varicella disease (B).
Maternal varicella before the 20th week of pregnancy
– risk to the foetus and management 
In addition to an increased risk of miscarriage
or intrauterine foetal death [37–39] (III) the main
risk in this phase of pregnancy is varicella in the
embryo or foetus (congenital varicella syndrome)
which is characterised by scarring skin lesions
(100%), hypoplasia or aplasia of limbs (86%), low
birth weight (82%), damage to the eyes (64%),
neurological disorders (30%) and retarded psy-
chomotor development (50%) (III). The risk of
congenital varicella syndrome is 0.4% when ma-
ternal varicella occurs in the first 13 weeks and 2%
between the 14th and 20th weeks. It practically
never occurs after the 20th week. Varicella during
pregnancy does not justify termination without
prior prenatal diagnosis (B). Detection of VZV in
the amniotic fluid by polymerase chain reaction
(PCR) is recommended for the prediction of con-
genital varicella syndrome in the event of varicella
before the 20th week of pregnancy, although there
is some controversy about its usefulness [40–42]
(C). Sonography provides the best assessment of
congenital varicella syndrome, and monthly
checks are indicated [43] (B). If a foetal abnormal-
ity is detected, the parents should be informed of
the possibility of associated brain damage [44].
Termination of the pregnancy should be discussed
(B).
If a VZV-seronegative pregnant woman is ex-
posed to VZV, administration of specific im-
munoglobulins (VZIG) or polyvalent im-
munoglobulins is recommended to prevent a se-
vere varicella disease (B). Passive immunisation
should be given within 72 to 96 hours after expo-
sure, but a favourable effect has also been observed
up to 10 days after exposure [38, 45]. A reduction
in the risk of congenital varicella syndrome could
Figure 1
Varicella in
pregnancy.
Varicella and pregnancy; risk according to the stage of gestation
Varicella and pregnancy; risk of severe neonatal varicella
Planning the birth according to the time of infection of the mother
Risk: for the foetus for the mother for the neonate
congenital varicella syndrome pneumonia* neonatal varicella
Action: prenatal diagnosis monitoring delay birth
possibly termination treatment
* The pregnant woman can develop varicella pneumonia during the full period of pregnancy, but a
more severe risk exists after 18th–20th weeks of pregnancy [Alonso AM. J Gynecol Obstet Biol Reprod.
1999;28:838].
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not be demonstrated but the incidence of foetal in-
fections appears to be reduced [41] (III). Various
forms of treatment, including aciclovir, do not pre-
vent vertical transmission (III). 
Maternal varicella in the period around the expected
birth date – risk to the foetus and management 
In the case of maternal varicella around term,
the clinical course of the infection in the neonate
depends on the time of transmission (intrauterine
or postnatal) and the presence or absence of ma-
ternal VZV-specific antibodies [46]. Transplacen-
tal transmission in the case of maternal viraemia
can lead to a high inoculum, and the absence of ma-
ternal antibodies can result in the same outcome as
in immunocompromised subjects. The combina-
tion of these two factors arises if the maternal ex-
anthema occurs during the period from 5 (or pos-
sibly 7) days before to 2 days after the birth (see
diagram). In this situation the rash develops in the
neonate 5–15 days after birth and a severe clinical
course is common with a fatality rate of up to 30%
in untreated children [47] (V). However, neonatal
varicella after the maternal rash appeared 5–21
days prior to birth has a good prognosis [48] (III).
Therefore, in the case of maternal exposure to
varicella in the period before term it is important
to prevent the birth from occurring in the critical
phase from 2 days before to 5 days after the devel-
opment of exanthema in the mother (C).
Varicella in the neonatal period
When maternal antibodies are present, neona-
tal varicella is usually mild, both after intrauterine
transmission (maternal exanthema more than 5–7
days before birth) and after postnatal exposure [49]
(III). The risk of severe neonatal varicella in the
case of postnatal transmission and absence of anti-
bodies is not known, but there have been only a
few reports of deaths in this situation [50] (V).
Nosocomial transmission to premature babies in
neonatal intensive care units has been reported
[51] and is feared, but can be avoided if the appro-
priate precautions are taken [52]. Meaningful, pri-
marily preventive, measures include ensuring the
VZV immunity of the staff (as a result of earlier in-
fection or vaccination) and a ban on visits by non-
immune persons after contact with varicella in the
incubation period or by people with varicella.
Administration of specific immunoglobulins
to the neonate cannot prevent neonatal varicella,
but no deaths and only 10–20% severe cases were
observed in two prospective studies on more than
150 neonates born to mothers with exanthema be-
tween 7 days before and 2 days after delivery [49,
53] (III). However, deaths have also been reported
after administration of immunoglobulins [54–57],
and so prompt treatment with aciclovir is recom-
mended [58] (C).
After administration of immunoglobulins it is
important to instruct the parents on what to do if
symptoms develop [58]. The antibodies adminis-
tered can extend the incubation period to 28 days.
In the case of varicella with systemic symptoms or
severe exanthema, intravenous treatment with aci-
clovir is recommended (C). Starting treatment as
soon as any blisters appear is a matter of dispute in
view of the large number of mild forms of the dis-
ease.
It is not recommended to separate the asymp-
tomatic neonate from its mother if she had vari-
cella exanthema at the time of the birth or devel-
ops it subsequently. The probability that the baby
has already been infected in utero or in postnatal
contact during the viraemic phase before develop-
ment of the exanthema is so high that the possible
remaining preventive effect of such a measure can-
not justify the far-reaching psychological effects of
absolute separation of mother and baby. Breast-
feeding is possible (C).
A common situation requiring consideration is
the presence of florid varicella in a sibling at the
time of discharge of the baby from hospital. If the
mother has immunity to varicella, the risk is very
low. If the mother is shown to be seronegative, an
attempt can be made to house the sick sibling else-
where. Administration of immunoglobulins is not
recommended [59].
Herpes zoster
Epidemiology
After a latency period of years or decades, VZV
can be reactivated and result in herpes zoster (HZ).
The annual incidence of HZ in the general popu-
lation is 1.3 to 3.4 per 1000 inhabitants [60, 61] (II).
In Switzerland an annual average of 13,000 pa-
tients with HZ can be assumed. The incidence in-
creases after the age of 50 years. Half of all 85-year-
olds have suffered HZ (II). About 1 in 20 immuno-
competent patients suffer a recurrence of HZ, usu-
ally in the same dermatome [61]. As HZ occurs
mainly in the elderly and the immuno-compro-
mised, an increasing number of patients with HZ
is to be expected in view of the demographic trend.
Herpes zoster in adults
HZ can occur in any dermatome but is most
frequently found in the thoracic or lumbar nerve
segments (T3-L2) and the distribution area of the
trigeminal nerve (V1-3). The preferred site is
dependent on gender and age [60, 61] (II). In the
majority of cases there are initially prodromes for
1–5 days, the quality and intensity of which vary
greatly. Pain in the area of distribution of the af-
fected spinal and cerebral nerves, pruritus, paraes-
thesia (including burning) or anaesthesia/hyper-
aesthesia can occur in addition to systemic signs.
Numerous papules develop in the affected der-
matome, in groups on an erythematous back-
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ground, and turn into blisters in 12–24 hours and
then into pustules. They are often accompanied by
severe pain. Haemorrhagic lesions and more rarely
necrosis can occur. In immunocompetent patients
the blisters start to dry out after 7–10 days with the
formation of crusts, which fall off after 2–4 weeks
[62]. Shorter and milder forms without progres-
sion to blisters can occur [63]. Exanthema may be
completely absent (Zoster sine herpete). Often there
is spread to adjacent dermatomes, while multiseg-
mental HZ of disparate dermatomes (HZ duplex or
multiplex) is rare [64]. HZ with a vesicular rash in
the external ear, auditive channel and/or in the
homolateral half of hard palate and tongue can be
accompanied by facial paresis and hypoacusia
(Ramsay-Hunt syndrome) [65].
The indications for antiviral therapy and the
dosage for HZ are summarised in table 5. If BVD
is used, attention must be paid to the contraindi-
cations. Recommendations for treatment of HZ
are in accordance with recently published guide-
lines from other countries [66, 67].
Herpes zoster in the immunosuppressed
The incidence of HZ is considerably increased
in the case of cellular immunodeficiency (eg HIV
infection, organ transplant recipients) [22, 26]. HZ
occurs in 5–32% of transplant recipients [23, 26,
68]. Necrotising forms of HZ and atypical presen-
tations with chronic ulcerations, hyperkeratotic-
verrucous or multiform skin lesions occur more
frequently in immunocompromised patients [69].
Immunocompromised patients are at increased
risk of disseminated mucocutaneous zoster and in-
volvement of internal organs. The fatality rate
reaches up to 28% [23, 24, 26]. Generalised HZ is
defined as dissemination with more than 20 vesi-
cles in disparate dermatomes [61, 70]. The treat-
ment of HZ in immunocompromised patients de-
pends mainly on the severity of the immunosup-
pression and the extent of the spread of the HZ
[22]. In the case of severe immunosuppression and
generalised HZ, intravenous antiviral therapy is
indicated [26, 27] (IA).
Herpes zoster ophthalmicus
Due to the high risk of severe lasting func-
tional impairment of the eye in the case of HZ oph-
thalmicus (HZO), immediate referral to the oph-
thalmologist is recommended even before HZO is
confirmed [71](IIIB). HZO develops as a result of
the spread of the reactivating VZV along the
branches of the trigeminal nerve that distribute to
the eye (V1 and V2; [72] [IB]). In almost all cases,
the first branch of the trigeminal nerve is affected,
and in 20% the second branch as well. Affection of
the supraorbital branch leads to increased involve-
ment of the upper lid. Lacrimal branch involve-
ment results in sicca syndrome and if the nasocil-
iary branch is affected, there is an increased risk of
eye damage (Hutchinson sign [73] [IB]). Oph-
thalmic zoster sine herpete and bilateral forms have
been described [74] (IVC). Eye complications are
observed in more than 50% of cases, even with
treatment [75] (IA). 
Even in younger, immunocompetent patients,
HZO is a clear indication for systemic antiviral
therapy [76–78] (IB). Systemic therapy should be
started as soon as possible, but can reduce the risk
of intraocular involvement by more than 50% even
if delayed beyond the 72-hour limit [79] (IB). For
symptomatic treatment, a tear film substitute can
also be considered, and careful local and systemic
steroid therapy should be considered per individ-
ual case [80] (I, B). The frequently prescribed local
antiviral therapy is of no additional benefit and is
therefore not recommended if systemic therapy is
required. 
Herpes zoster in children
HZ in children is very rare with an estimated
incidence of 0.74 cases/1000 children per year  [81]
(III). Varicella in utero or during the first year of
life increases the risk of HZ in early childhood [82]
(III). The symptoms are the same as in adults, al-
though the skin lesions are less prominent and the
symptoms of acute neuritis are mild or absent. Un-
like adults, children do not suffer post-herpetic
neuralgia [83] (III). If the cranial nerves are af-
fected, conjunctivitis, dendritic keratitis, anterior
uveitis, iridocyclitis, retinitis and facial paresis can
occur as complications [84, 85]. Lumbosacral HZ
can be complicated by neurogenous bladder dys-
function or ileus with intestinal obstruction [84,
86]. Antiviral therapy is not necessary in children
with uncomplicated HZ not affecting the face (C). 
Herpes zoster in pregnancy
Unlike varicella, HZ during pregnancy does
not seem to pose a risk of congenital infection, ir-
respective of the time between HZ and birth [38,
87, 88] (III). Pregnancy has no effect on the course
of HZ. The indications for antiviral therapy cor-
respond to those for adults (C).
Post-herpetic neuralgia
Post-herpetic neuralgia (PHN) can be defined
as chronic neuropathic pain that persists or devel-
ops 30 days after the skin lesions of HZ have healed
[89]. PHN is often therapy refractory and may per-
sist for several months to years [90]. PHN occurs
in 10–20% of all HZ patients, and is rare in pa-
tients aged <40 years. Different incidence rates
have been reported which may be in part due to
different definitions of PHN. The incidence of
PHN increases with age. In HZ patients >50 years
the risk of PHN is 50%. Age (>50 years), pain dur-
ing the prodromal and acute phase of the HZ and
cranial or sacral location of HZ are regarded as risk
factors for PHN (II). PHN is a neuropathic pain
and develops primarily as a result of lesions to the
pain-mediating nervous system itself. PHN can be
of various forms and may present with sharp, deep
boring, burning pain sensations or itching and can
be associated with hyperaesthesia or allodynia.
The sequelae include chronic fatigue, sleep disor-
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ders, depression and a general reduction in quality
of life.
Moderately severe and severe pain during the
prodromal and acute phase is an indication for
early antiviral therapy. The risk of PHN is reduced
by the antivirals licensed for the treatment of HZ
(A). Antiviral treatment for more than 7 days is not
indicated [78]. Immediate and lasting analgesia
right from the early phase may have a preventive
effect on the development of PHN [91]. Treat-
ment of established PHN is symptomatic and cor-
responds in general to the treatment of neuro-
pathic pain. Centrally acting modulators have the
most effect (table 5). The evidence supports the
oral use of tricyclic antidepressants, certain opi-
oids, and gabapentinoids in PHN. Topical therapy
with lidocaine patches and capsaicin is similarly
supported [92, 93]. Systemic steroids improve the
quality of life in the acute phase of zoster-associ-
ated pain but do not reduce the risk of PHN [80].
The choice of the long-term treatment should
consider side-effects such as sedation or mood en-
hancement. 
Investigation of underlying diseases
Unisegmental HZ in immunocompetent eld-
erly patients is not an indication for a screening in-
vestigation for malignancies [94,95] (IIIB). Nor
could any such connection be found in children
[96] (IIIB). In hospitalised patients with HZ, a 1.2-
fold increase in the risk of malignancies, especially
lymphoproliferative diseases, has been detected
[97] (IIIC). Screening is not recommended be-
cause the detection rate is low. HZ in children does
not require any further investigation. HZ in young
adults (under 40 years of age) is 10–20 times more
frequent in conjunction with HIV infection than
in subjects with a healthy immune system. The cu-
mulative incidence in HIV patients over ten years
is 41% [98, 99] (II). In the case of corresponding
risk behaviour, an HIV test should be carried out
(IIB). 
Varicella zoster virus infections in hospital
Patients with VZV infections are mainly hos-
pitalised in three situations: (1) in the case of res-
piratory complications of varicella, which occur
mostly in adults, (2) if the extent of the HZ is se-
verely impairing the patient’s general condition or
if there is a risk of complications (eg Herpes zoster
ophthalmicus) or if such complications are pres-
ent, and (3) in immunocompromised subjects with
multisegmental or disseminated HZ.
From the standpoint of hospital hygiene, the
infectivity of patients with VZV infections is rele-
vant for hospitalisation or outpatient care. Vari-
cella is highly contagious as the VZV is excreted in
respiratory secretions and transmitted by aerosol.
In patients with HZ of limited extent there is no
or extremely little aerosol infectivity, as VZV is not
released into the air in sufficient concentrations
from the skin lesions. Transmission by direct
contact with non-crusted lesions is possible (IV).
In patients with limited HZ, topical covering of
skin lesions but not isolation measures is recom-
mended. 
Hospital hygiene measures include isolation of
patients with varicella during inpatient care, in
order to protect other patients and non-immune
staff from infection. Isolation is done in single
rooms which can only be entered by immune
people. No particular protective measures are
required to protect immune individuals. These
protective measures also apply for patients with
disseminated, reactivated VZV infection or with
multi-segmental HZ, as these patients may be
slightly more contagious, although conclusive data
in this respect are missing.
Medical institutions should take precautions
to prevent transmission of VZV infections from
infected staff. As 80–95% of adults are immune to
VZV in the industrialised countries, the propor-
tion of medical staff who is potential carriers of
VZV infection is relatively low. Regarding non-
immune medical staff (including medical stu-
dents), there are two possible procedures which are
based on the medical history relating to varicella.
Individuals with a positive history for varicella can
be assumed to be immune. When the history is not
conclusive the immune status can be tested by
serology. When the immune status is negative the
person should be vaccinated against VZV. On the
other hand, vaccination of all those with a negative
history can be carried out automatically as a prag-
matic measure. Complete immunity of the med-
ical staff is particularly important in paediatric,
neonatal and obstetric departments. Many hospi-
tals follow the strategy that all medical staff must
demonstrate immunity to VZV. A recent cost-ef-
fectiveness analysis compared the cost per avoided
case of varicella among a theoretical cohort of
63,353 physician and nurses aged less than 45 years
in Israel. Screening and vaccination of susceptible
workers using anamnestic selection was expected
to reduce future cases, within 20 years since vacci-
nation, from 58.3 to 33.0 with an incremental cost
of US $ 23,713 per avoided case. Using only sero-
logical tests to detect susceptible workers would
prevent an additional 5.7 cases with an incremen-
tal cost of US $ 206,692 per avoided case [100]. 
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Diagnosis
Detection of the virus 
The virus or its components (eg an envelope
protein or the virus genome) can be detected using
various techniques (table 6), if a diagnosis cannot
be made clinically. The following possibilities for
detecting VZV are available:
– virus detection by culture
– detection of virus antigen by means of specific
antibodies
– detection of sequences of the virus genome
after enzymatic amplification (polymerase
chain reaction = PCR)
The most widely employed methods are sum-
marised in table 6. Due to their differing sensitiv-
ity and specificity, application of these techniques
depends on the stage of the disease. Detection of
VZV by virus culture is a relatively time-consum-
ing detection technique, which requires a special
virus transport medium and is less sensitive than
direct detection by immunofluorescence or elec-
tron microscopy. By combining culture (“shell
vial” technique) and immunofluorescence, the de-
tection can be considerably accelerated and the
sensitivity increased. Detection of the virus
genome by polymerase chain reaction (PCR) has
now become the method of choice for various
sample materials such CSF or aqueous humour.
Compared with culture, the sensitivity of the
VZV-specific PCR with swabs is 95% with a speci-
ficity of 100% [101, 102]. Pre-analysis or labora-
tory-associated contaminations must be avoided in
order to avoid false positive results [102]. 
Detection of antibodies
The most important indication for VZV serol-
ogy is ascertainment of immune status, ie detec-
tion of VZV-specific IgG in the case of potentially
increased risk of disease or transmission, such as
exposure to varicella in pregnancy or immune dys-
function before transplantation or chemotherapy.
However there is no international standard which
makes it possible to determine the minimal protec-
tive titre value. The diagnostic value of detection
of VZV-specific IgM is limited, on the one hand,
by the commonly straightforward clinical diagno-
sis of the primary infection as varicella, and on the
other hand, by low sensitivity and specificity in
other manifestations such as herpes zoster. Im-
munofluorescence or the ELISA technique is
mainly used for the detection of VZV-specific an-
tibodies. With the most sensitive methods anti-
bodies can be measured just 3–4 days after the de-
velopment of the exanthema. The detection of
VZV-specific intrathecal antibody production is a
rare special indication when VZV-infection of the
CNS is suspected, which can only be detected in
later phases of the disease. In general virus detec-
tion should be the preferred mode of detection.
Method Properties Sample Sensitivity Specificity
Immunofluorescence Rapid (result in <4 h possible) Swabs from lesions 80% 90%
(detection of infected cells) Only for florid lesions with blister base on slide
Price: 25 Tax points Only in specialised labs
Polymerase chain reaction Most sensitive method Samples without additives (native) >95% >95%
(PCR) Result in 24–48 h Cerebrospinal fluid
Simple transport Aqueous humour
Price: 170 Tax points Any material Skin lesions
Only in specialised labs Blister content
EDTA-blood, tissue not known
Virus detection by cell culture Only for florid lesions Skin/mucosa lesions 16–29% >95%
Virus transport medium, (Stage)
Price: 80 Tax points Transport must be rapid, Blister content decreasing 
cooled, protected from light Ulcers according
Result in 5–14 days Crusts to stage
Not adequate for CSF Tissue not known
Only in specialised labs
All the prices for analysis re-reimbursed by the insurance for social security are calculated in tax points. 
All the analyses executed by medical laboratories are billed in tax points. Currently one tax point corresponds to 0.90 CHF.
Table 6
Diagnosis of VZV
infection.
Varicella zoster virus vaccination
Attenuated VZV live vaccines based on the
Oka strain have been available since the eighties
and have been recommended in the USA as rou-
tine vaccination for children after 12 months of age
and as a booster for older children without a
history of varicella since 1996 [103]. One dose is
administered at the age of 1 to 10 years, and two
doses 4 weeks apart after the age of 11 years. The
vaccination is well tolerated. Undesirable effects
are observed in 5–35%. About 20% experience
local reactions at the injection site. 3–5% develop
a localised or generalised varicella-like rash (I)
[103]. The vaccination produces seroconversion in
90–100% (I) and gives >80% of vaccinees com-
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Indications E 11–15-year-old adolescents without history of varicella. 
E People who are not immune (serum IgG negative) and have an increased risk of varicella complications:
– People with leukaemia or malignant tumours (vaccination during clinical remission), before immunosup-
pressant treatment or organ transplant, children with HIV infection (if CD4-lymphocytes >500/ml 
age 1–5 years, >200/ml age >6 years)
– Children with severe neurodermatitis
– People in close contact with the above (siblings, parents)
– Medical and care staff (especially in gynaecology/obstetrics, paediatrics, oncology, intensive care, 
care of immunosuppressed patients).
E Booster vaccination in older adolescents and young adults (<40 years), who have not had varicella, 
especially women of childbearing age.
Administration E Age 12 months to 11 years: 1 dose subcutaneously.
E >11 years: 2 doses subcutaneously 4 weeks apart
Vaccine Varilrix®
Contra-indications E Age <12 months.
E Anaphylactic reaction to previous vaccination or a vaccine component.
E Cellular immune deficiency.
E Advanced HIV infection and AIDS.
E Steroid treatment (prednisone: ≥2 mg/kg/d or ≥20 mg/d for >14 days).
E Treatment with immunoglobulins or blood products (waiting period of at least 5 months).
E Pregnancy (after vaccination contraceptive measures should be taken until one month after the second dose).
E Severe acute disease
Table 7
Varicella vaccination
in Switzerland [113].
plete protection, >90% protection against moder-
ately severe and severe courses (I) [104]. In a more
recent case-control study the protective effect in
the overall observation period was 87% [105], but
fell as the time since vaccination increased (97% in
the first year, 84% after 2–8 years) (IV) [106]. The
protective effect also decreased if the vaccination
had been given before the age of 15 months [107].
Breakthrough infections with the wild type virus
can be as contagious as varicella in unvaccinated
subjects [108]. The question is whether a second
vaccine dose is necessary for children. A follow-up
of vaccinees for 10 years showed that children who
have had two doses of vaccine have a lower risk of
varicella than children who have had only one dose
(2.2% versus 7.3%) (III) [106]. On the other hand,
new data from the USA show that the one-dose
regimen demonstrably leads to a considerable re-
duction in varicella complications [109]. Vaccina-
tion reduces the risk of HZ in VZV-seropositive
patients with leukaemia and kidney transplant re-
cipients (III) [110–112]. 
Recently, a vaccine with a considerably higher
virus concentration was studied in a randomised,
double-blind, placebo-controlled trial with 38,546
patients 60 years of age or older [89]. The use of
this life-attenuated vaccine (Oka/Merck VZV vac-
cine) reduced the incidence and burden of illness
of herpes zoster by 51.3% and 61.1%, respectively
(I). In addition, it reduced the incidence of post-
herpetic neuralgia by 66.5% in vaccinees (I). This
vaccine has not yet been licensed. In Switzerland
varicella vaccination is recommended for adoles-
cents and young adults with a negative varicella
history and for people with specific risks. The rec-
ommendations of the Federal Office of Health
(BAG) which have been published in 2005 and the
method of administration and contra-indications
are given in table 7 [113].
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